Management
Acute management
Refer to the flowchart [PDF 328.51 KB] for a summary of the recommended emergency management and medications for a pre-school child with a wheezing illness:
Management comprises of medications targeted at relieving acute bronchospasm, alleviating lower airway inflammation, and providing respiratory support in the form of oxygen and non-invasive ventilation. Steroids are not indicated in pre-school children who present for the first time or infrequently with a mild to moderate wheeze.
Repeated clinical assessment following each treatment is essential to determine the change in clinical symptoms (improvement/no change/deterioration). This should be well documented in the patient clinical notes.
Bronchodilators
Salbutamol (short acting inhaled beta2 agonist) is recommended for all pre-schoolers with wheeze.9
Monitor oxygen saturations continuously if administering Salbutamol more often than every two hours. Bronchodilators may produce a paradoxical effect in children with underlying structural abnormalities such as bronchomalacia or tracheomalacia. 10
Inhaled Salbutamol dosing for the treatment of wheeze in pre-school childrenMetered dose inhaler (MDI)* 100 micrograms (via spacer +/- mask*)
|
Age 1 to 5 years: 6 puffs
|
Nebulised |
Age 1 to 5 years: 2.5 mg
|
Salbutamol burst |
Administer three doses as above at twenty-minute intervals
|
Continuous nebulised Salbutamol |
Neat Salbutamol nebuliser solution (5 mg/mL), replenish where reservoir empty. Use 5 mg/1 mL nebules or 30 mL multi-use bottle.
|
* Use mask also if unable to form a reliable seal on spacer
Alert
Cumulative Salbutamol doses can cause agitation, tremor, tachycardia, tachypnoea and rarely, hypertension. Raised lactate, hypokalaemia and raised glucose on VBG are markers of salbutamol toxicity.
MDI and spacer vs nebuliser
- MDI usually preferred as:
- faster (nebuliser requires a child to sit still for at least 10 minutes).
- less facial and oropharyngeal deposition of medication (nebuliser delivers at best 10% of the prescribed drug to the lungs and child may experience side effects of systemic absorption such as tachycardia and tremor)
- Nebuliser is recommended for children who are struggling with their breathing and/or not able to co-ordinate taking a deep breath through the spacer.
How to use a spacer
- Prime spacer before use to negate electrostatic charge (and optimise drug delivery) with 10 Salbutamol puffs.
- Shake MDI before each puff. Administer one puff at a time into the spacer (+/- face mask).
- The child clears the medication from the spacer by taking four breaths following each puff.
Weaning salbutamol
Stretching the time between Salbutamol doses should be based on an assessment on the child. This should be done in collaboration with the child and caregiver30 and include:
- respiratory distress: decreased work of breathing (subcostal and intercostal recession/ tracheal tug /nasal flaring)
- activity level: decreasing lethargy, increasing alertness
- respiratory rate: decreasing to within normal limits for age
- heart rate: decreasing to within normal limits for age
- speech: able to talk in sentences
- auscultation: air entry improved, wheeze reduced or appearance of wheeze in previously quiet chest (note wheeze alone is not an indication for Salbutamol)
- cough: reduction or change in cough i.e. becomes looser
- oxygen saturations: increasing oxygen saturations and decreasing oxygen requirement
Ipratropium bromide
Not routinely recommended as there is insufficient evidence to support use.11
Consider for children with severe symptoms following Salbutamol MDI or in combination with Salbutamol in nebuliser reservoir.12
Ipratropium dosing for the treatment of wheeze in pre-school childrenMetered dose inhaler (MDI) 20 micrograms* |
4 puffs (84 micrograms) via spacer every twenty minutes for three doses
|
Nebulised |
250 micrograms nebulised every twenty minutes for three doses
|
*Metered dose inhaler. Always use via spacer. Use mask also if unable to form a reliable seal on spacer.
Steroids
Steroids are recommended for pre-school children with wheeze with:
- frequent episodes
- ongoing bronchodilator use more frequently than every two hours
- severe or life-threatening symptoms
- a requirement for intensive care unit admission
Consider steroids for pre-school children with a history suggestive of an asthma phenotype e.g. atopy and maternal family history of asthma.
While the evidence is still evolving, steroids are not currently recommended for pre-school children who present for the first time or infrequently with mild to moderate wheeze.
Some studies suggest that steroids do not reduce symptom severity or the need for hospital treatment in pre-school children with mild to moderate wheeze.8 A large randomised, double-blind, placebo-controlled trial found no significant difference in the duration of hospitalisation in children with mild to moderate wheezing associated with viral infection in those given oral steroids compared to placebo.13 However, a recent Australian study concluded that Prednisone had a clear benefit at reduced length of stay in children with mild-moderate viral associated wheeze.14
The systemic steroid of choice is oral Prednisone/Prednisolone. Studies have shown that Dexamethasone may be a suitable alternative steroid. In a recent paediatric study, a single 0.3 mg/kg dose of Dexamethasone was found to be as effective as a three-day course of Prednisone to Prednisone 0.1 mg/kg for three days.15 However, Dexamethasone suspension is not readily available in the community or non-tertiary hospitals.
Prednisolone (Oral) dosing for the treatment of wheeze in pre-school childrenDay | Dose |
---|
Day 1 |
2 mg/kg (maximum 50 mg)
|
Day 2 and 3 |
1 mg/kg Can extend course to five days if still symptomatic after three-day course
|
Oxygen
Target oxygen saturations (SpO2) and the use of low and high flow oxygen therapy is highly variable depending upon local practice and resource availability. Follow local policies where available.
There is no evidence to clearly define an optimal oxygen saturation (SpO2) target and therefore the threshold for administration of supplemental oxygen for young children with respiratory illnesses. Consensus opinion supports a target of SpO2 of 94% or above. Lower saturations may be tolerated depending upon institutional practice. A study in infants (age less than 12 months) with bronchiolitis showed that a target SpO2 of more than 90% was as safe and clinically effective as 94%.16 This study may influence future practice in other respiratory illnesses. A current randomised controlled trial studying high flow oxygen therapy for children with acute hypoxemic respiratory failure uses a cut off of less than or equal to 92% for the commencement of oxygen supplementation.17
Low flow oxygen should not be given to children for work of breathing in isolation, and the practice of “fly-by” oxygen (i.e. leaving a mask adjacent the patient’s face) is discouraged. Desaturations below the local limit for less than five minutes during sleep with rapid self-correction does not mandate increasing or commencing supplemental oxygen. Nursing staff may initiate supplemental oxygen however, a medical review should be requested at the time to ascertain the cause of deterioration. Oxygen should be prescribed on an oxygen order form as per local practice.8
Continuous oximetry should be performed in children requiring oxygen.
Low flow oxygen for infants with bronchiolitis by method of delivery Nasal prongs | Hudson mask |
---|
Maximum flow rate of 2 L/min
|
Commence at a minimum flow rate of 4 L/min to ensure adequate delivery if oxygen requirement is greater than 2 L/min
|
Intravenous Magnesium sulphate
Seek senior emergency/paediatric input as per local practice for child requiring magnesium sulphate. Consider contacting paediatric critical care.
Consider in child with severe/life-threatening respiratory distress who is not responding to inhaled bronchodilators.
Magnesium sulphate is thought to act by decreasing the uptake of calcium by bronchial smooth muscle cells, which leads to bronchodilation. In addition, it may have a role in inhibiting mast cell degranulation, which reduces inflammatory mediators.18,19 There is no clear evidence to support use for the treatment of pre-school wheeze.11
Alert
Prescribe Magnesium in mmols and administer using safety software syringe drivers.
Administer Magnesium sulphate using safety software syringe drivers with a standard concentration of 0.5 mmol/mL. e.g. a 10 kg child, the Magnesium sulphate dose is 0.2 mmol/kg = 2 mmol. This translates to 4 ml of 0.5 mmol/mL solution and must be administered through a safety software syringe driver over 10 – 20 minutes to minimise the risk of too rapid administration and dosing errors.
Magnesium sulphate (IV) dosing for the treatment of wheeze in pre-school childrenBolus dose |
0.2 mmol/kg (equivalent to 50 mg/kg) infused intravenously over twenty minutes (maximum 10 mmol = equivalent to 2,500 mg) Doses up to 0.4 mmol/kg (maximum of 8 mmol) have been used. Must be administered in syringe driver using safety software. |
Side effects |
Usually minor, including epigastric or facial warmth and flushing, pain and/or numbness at infusion site and dry mouth. Severe reactions include allergy, hypotension, respiratory depression and circulatory collapse.
|
Monitoring |
Full cardiac monitoring with blood pressure every five minutes. Cease infusion if hypotension persists. Monitor knee reflexes if repeating dose to assess for magnesium toxicity which can result in respiratory failure. Cease magnesium if reflexes absent.
|
Intravenous Salbutamol
Contact paediatric critical care specialists (onsite or via RSQ) for children requiring Salbutamol IV.
Salbutamol IV is only recommended for children with a very severe acute wheeze.20
Administer an initial bolus dose and monitor closely for signs of Salbutamol toxicity. Slow or cease infusion if significant concerns. Evaluate the clinical response to this initial dose and consider progression to a Salbutamol IV infusion.
Salbutamol (IV) dosing for the treatment of wheeze in pre-school childrenBolus dose |
100 microgram/kg infused over twenty minutes (maximum 5 milligrams)
|
Infusion |
1-2 microgram/kg/min (to maximum weight 50 kg)
|
Side effects |
Cumulative doses of Salbutamol can cause agitation, tremor, tachycardia, tachypnoea and rarely, hypertension. Raised lactate, hypokalaemia and raised glucose on VBG are markers of Salbutamol toxicity.
|
Monitoring |
Full cardiac monitoring Monitor venous potassium levels.
|
Intravenous steroids
Seek senior emergency/paediatric input as per local practice for children requiring steroids IV. Consider seeking paediatric critical care input (onsite or via RSQ).
Consider in a child with severe wheeze who cannot tolerate oral medication or has a decreased conscious level.
Steroid (IV) dosing for the treatment of wheeze in pre-school childrenHydrocortisone (IV) |
4 mg/kg (maximum 200 mg) then every six hours on day one.
|
OR Methylprednisolone (IV) |
1 mg/kg (maximum 60 mg) then every six hours on day one.
|
High flow nasal cannula oxygen (HFNC) therapy and non-invasive ventilation (NIV)
Seek urgent paediatric critical care advice (onsite or via RSQ) for a child requiring HFNC therapy.
HFNC therapy may help avoid intubation but can also provide pre-oxygenation whilst preparation for inevitable intubation is underway.
A randomised controlled study assessing the efficacy of HFNC therapy for children with acute hypoxemic respiratory failure including patients with pre-school wheeze is currently being conducted. The findings will improve our understanding of the role of HFNC therapy for pre-school wheeze.17
HFNC therapy and ongoing bronchodilator therapy
Providing bronchodilator therapy at the same time as HFNC therapy is challenging. A specific circuit (preferred) or a transient decrease to low flow oxygen is required. Where a circuit is not available and the child is too unwell to remove HFNC therapy, a bolus or infusion of Salbutamol IV is recommended.
Potential concerns [PDF] (access via QH intranet) have been raised regarding the use of HFNC therapy.
Follow local policies and procedures for nursing ratios and ward location. View CHQ Nasal High Flow Therapy Guideline [PDF 609.52 KB].
NIV including continuous positive airways pressure (CPAP) or bi-level positive airways pressure (Bi-PAP) can also be considered to help avoid intubation or pre-oxygenate for inevitable intubation e.g. child with a normal level of consciousness who is unable to maintain SpO2 greater than or equal to 94% despite oxygen via a Hudson mask with reservoir, or has deteriorating work of breathing with increasing fatigue, tachycardia, and tachypnoea.
Medications not routinely recommended
The following medications are not routinely recommended in the acute management of pre-school wheeze:
- hypertonic saline
- oral beta2 agonists (e.g. Salbutamol syrup) due to systemic side effects18
- inhaled corticosteroids1
- intermittent montelukast18
Chronic management
Preventer medication may be considered for children with recurrent episodes of multi-trigger wheeze (MTW). Medication should be prescribed by the child’s General Practitioner or Paediatrician.
Preventative medications for children with recurrent wheeze episodes (multi-trigger wheeze)Medication | Management |
---|
Inhaled corticosteroids |
3-month trial may be considered A RCT of long-term inhaled corticosteroid demonstrated improvement (smaller effect than school-aged-children and adults) in symptoms, exacerbation rates, lung function, and airway hyper-responsiveness.21,22 |
Leukotriene antagonists |
Daily montelukast may be considered as an alternative to inhaled corticosteroids for toddlers with MTW who are at high risk for asthma.23 Parents should be counselled on potential side effects including headaches and mood disturbance/depression. |